Dr. Doris Hansen, MD

Dr. Hansen practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Hansen's NPI, 1881958270, was assigned on June 29, 2012. Dr. Hansen graduated from St. George's University School of Medicine in 2012. Dr. Hansen's Mississippi license number on file is 855-L.

Dr. Hansen's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Hansen's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Hansen to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hansen practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Hansen's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Hansen is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Hansen's licenses on file in 2 states: Mississippi and Florida.

Dmand AI lists lymphoma and multiple myeloma among the conditions Dr. Hansen treats.

CMS data shows 212 Medicare services from Dr. Hansen across 4 procedure codes in 2024, for 68 Medicare patients. Medicare paid $14,829 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 68 Medicare patients who saw Dr. Hansen in 2024. The largest group is 65 to 74, with 43 patients. 74% of them have high blood pressure, and 68% have high cholesterol. Their average risk score is 3.42, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hansen's median patient age at 69, with 49% women.

In 2024, Dr. Hansen wrote 202 Medicare Part D claims for 62 patients. 92% of them were for generic drugs. CMS names the drug for 102 of them, across 5 drugs with 11 or more claims each, at $4,156 in total drug cost. In 2023, CMS named 127 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Hansen for performance year 2024, reported as part of a group. Dr. Hansen accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hansen as offering telehealth.

Dmand AI links 41 papers to Dr. Hansen, published from 2021 to 2025. 2023 was the busiest year, with 9. The most frequent topics are Multiple Myeloma, Receptors, Chimeric Antigen and Immunotherapy, Adoptive. Dr. Hansen has published most often in Blood Adv. Dr. Hansen's most frequent co-authors are Frederick Lundry Locke, MD, Melissa Alsina, MD and Taiga Nishihori, MD.

Dmand AI links Dr. Hansen to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Multiple Myeloma and Blood Protein Disorders.

CMS Open Payments shows 382 general payments to Dr. Hansen from 42 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 72% of the total. Janssen Pharmaceuticals, Inc paid the most, $74,487.

Dr. Hansen graduated from St. George's University School of Medicine in 2012.

Dr. Hansen is in network with 7 carriers, including Elevance, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 5. Check the plan with the practice before a visit.